PSMA-PET/CT、胆碱-PET/CT、NaF-PET/CT、MRI与骨闪烁显像在前列腺癌骨转移诊断中的比较:系统评价与Meta分析
该系统评价与Meta分析检索1990年1月至2018年9月PubMed和Embase文献,比较PSMA-PET/CT、胆碱-PET/CT、NaF-PET/CT、MRI与骨闪烁显像诊断前列腺癌骨转移的性能;PSMA-PET/CT基于患者的敏感度0.97、特异度1.00最高,NaF-PET/CT基于病灶敏感度0.97最高,骨闪烁显像最低(0.68)。
要点
- PSMA-PET/CT基于患者诊断骨转移的汇总敏感度0.97、特异度1.00,均为最高。
- NaF-PET/CT基于病灶汇总敏感度0.97最高,骨闪烁显像0.68最低。
- PSMA-PET/CT特异度显著优于骨闪烁显像,其余方法间相似。
核心结论
- PSMA-PET/CT检测前列腺癌骨转移的基于患者敏感度和特异度最高。
- NaF-PET/CT和MRI的敏感度优于胆碱-PET/CT和骨闪烁显像。
- PSMA-PET/CT特异度显著优于骨闪烁显像,其余方法间相似。
- 基于病灶,NaF-PET/CT敏感度最高,PSMA-PET/CT敏感度高于胆碱-PET/CT和MRI,骨闪烁显像敏感度最低。
研究设计与样本
- 系统评价与Meta分析,检索PubMed和Embase 1990年1月至2018年9月发表文献。
- 两名评价者独立提取敏感度、特异度及真阳性、假阳性、真阴性、假阴性数。
- 计算各方法汇总敏感度、特异度及95%CI,并计算诊断比值比、绘制SROC曲线、获得AUC、Q*值及95%CI。
诊断标准与关键数值
- 基于患者汇总敏感度:PSMA-PET/CT 0.97、胆碱-PET/CT 0.87、NaF-PET/CT 0.96、MRI 0.91、骨闪烁显像0.86。
- 基于患者汇总特异度:PSMA-PET/CT 1.00、胆碱-PET/CT 0.99、NaF-PET/CT 0.97、MRI 0.96、骨闪烁显像0.95。
- 基于患者汇总诊断比值比:PSMA-PET/CT 504.16、胆碱-PET/CT 673.67、NaF-PET/CT 242.63、MRI 114.44。
- 基于患者AUC:PSMA-PET/CT 1.00、胆碱-PET/CT 0.99、NaF-PET/CT 0.99、MRI 0.98、骨闪烁显像0.95。
- 基于病灶汇总敏感度:PSMA-PET/CT 0.88、胆碱-PET/CT 0.80、NaF-PET/CT 0.97、MRI 0.81、骨闪烁显像0.68。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: A systematic review and meta-analysis to compare the diagnostic performance of prostate-specific membrane antigen (PSMA)-PET/CT, choline-PET/CT, Sodium Fluoride (NaF) PET/CT, MRI, and bone scintigraphy (BS) in detecting bone metastases in patients with prostate cancer.
METHODS: We searched PubMed and Embase for articles published between January 1990 and September 2018. Two evaluators independently extracted the sensitivity, specificity, the numbers of true and false positives, and true and false negatives. We calculated the pooled sensitivity, specificity, and 95% confidence intervals (CI) for each method. We calculated the tests' diagnostic odds ratios (DOR); drew the summary receiver operating characteristic (SROC) curves; and obtained the areas under the curves (AUC), Q* values, and 95% CIs.
RESULTS: The per-patient pooled sensitivities of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and BS were 0.97, 0.87, 0.96, 0.91, and 0.86, respectively. The pooled specificities were 1.00, 0.99, 0.97, 0.96, and 0.95, respectively. The pooled DOR values were 504.16, 673.67, 242.63, and 114.44, respectively. The AUC were 1.00, 0.99, 0.99, 0.98, and 0.95, respectively. The per-lesion pooled sensitivities of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone imaging were 0.88, 0.80, 0.97, 0.81 and 0.68, respectively.
CONCLUSIONS: According to the meta-analysis, PSMA-PET/CT had the highest per-patient sensitivity and specificity in detecting bone metastases with prostate cancer. The sensitivities of NaF-PET/CT and MRI were better than those for choline-PET/CT and BS. The specificity of PSMA-PET/CT was significantly better than BS. Others were similar. For per-lesion, NaF-PET/CT had the highest sensitivity, PSMA-PET/CT had higher sensitivity than choline-PET/CT and MRI, and BS had the lowest sensitivity.
引用
- Zhou J, Gou Z, Wu R, et al. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol. 2019. PMID: 31127357. doi:10.1007/s00256-019-03230-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。